IDXX 8-K Current Reports
IDEXX LABORATORIES INC /DE - 204 current reports
IDEXX LABORATORIES INC /DE 8-K Report, Bylaw Amendment (May 15, 2026)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 15, 2026, detailing significant corporate governance changes approved by shareholders at the May 12, 2026 annual meeting. The primary focus is the amendment to the Certificate of Incorporation and By-Laws to declassify the Board of Directors over a three-year period, with all directors to be elected annually starting in 2029. This move enhances shareholder oversight and aligns with modern corporate governance trends, making the board more directly accountable to shareholders. Furthermore, shareholders approved amendments granting a right to call a special meeting to those holding at least 25% of the company's capital stock continuously for at least one year. This provides a critical mechanism for shareholders to address urgent matters outside of the regular annual meeting schedule, increasing their influence and ability to effect change. The report also confirms the ratification of PricewaterhouseCoopers LLP as the independent auditor and the advisory approval of executive compensation, alongside the election of three Class II directors.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (May 5, 2026)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 5, 2026, to report its financial results for the quarter ended March 31, 2026. The filing primarily furnished a press release containing these results, which is attached as Exhibit 99.1. Investors should note that this information is being furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings, unless specifically stated. While the specific financial figures from the press release are not detailed within the 8-K text itself, this report serves as the official notification to the market of IDEXX's first-quarter performance. Investors seeking detailed insights into revenue, profitability, and any forward-looking statements will need to refer to the furnished press release (Exhibit 99.1).
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Mar 26, 2026)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on March 26, 2026, to report the departure of Dr. Nimrata Hunt, Executive Vice President of Global Strategy and Commercial, effective April 13, 2026. This departure was a mutual agreement, and Dr. Hunt will provide advisory services until July 13, 2026. The company has entered into a separation agreement that outlines the terms of her exit and advisory role. Investors should note the financial implications of Dr. Hunt's departure, including a separation package totaling approximately $2.24 million in salary continuation and target bonuses, along with COBRA premium costs, transition assistance, and tax/financial planning reimbursements. The company is classifying this as a termination without cause. The agreement also includes standard clauses like general release of claims, non-disparagement, and ongoing adherence to restrictive covenants. This filing primarily addresses a significant executive transition and associated costs.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Feb 13, 2026)
IDEXX Laboratories, Inc. (IDXX) announced a change in its Board of Directors composition. Ms. M. Anne Szostak has notified the company of her intention to retire from the Board, effective immediately after the 2026 Annual Meeting of Stockholders on May 12, 2026. Her retirement is not due to any disagreements concerning the company's operations or policies, indicating a smooth transition. The company expressed gratitude for her significant contributions and leadership since 2012. The Board will reduce the size of the Class III directors upon Ms. Szostak's retirement. This reduction, however, will be offset by the previously announced appointment of Michael G. Erickson, PhD, as a Class II director, also effective immediately following the 2026 Annual Meeting. Investors should note that these changes are procedural and do not appear to reflect any underlying issues with the company's performance or governance.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Feb 2, 2026)
IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report, filed on February 2, 2026, primarily serves to furnish the accompanying press release containing these financial details. Investors should note that the information provided in this filing is furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, nor is it automatically incorporated into other filings unless specifically referenced. The key takeaway for investors is the announcement of the company's performance for the recently concluded fiscal year and the final quarter. While the specific financial figures are contained within the furnished press release (Exhibit 99.1), this 8-K filing formally brings those results into the public domain. Investors interested in IDXX's operational and financial condition should refer to the press release for detailed metrics, revenue figures, profitability, and any forward-looking statements or guidance.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Jan 13, 2026)
IDEXX Laboratories, Inc. (IDXX) announced a CEO transition plan, with current President and CEO Jonathan (Jay) Mazelsky stepping down on May 12, 2026, and transitioning to the role of Executive Chair of the Board. He will retire in May 2027. Dr. Michael Erickson, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will assume the roles of President and CEO and join the Board. Dr. Erickson has a strong background in healthcare technology and innovation, having been with IDEXX since 2011 and previously consulting with McKinsey & Company. This leadership change is designed to ensure a smooth handover and leverage Dr. Erickson's extensive experience within the company. The filing also details the compensation arrangements for both Mr. Mazelsky in his new role and Dr. Erickson as he takes on the CEO position. Dr. Erickson's compensation package includes a $1 million base salary, a target bonus of 120% of base salary, and a significant long-term incentive equity award valued at no less than $7.8 million for fiscal year 2026, comprising stock options and performance-based RSUs. Mr. Mazelsky will receive an annual base salary of $1,150,000 as Executive Chair, along with specific bonus and equity arrangements for fiscal year 2026. Both executives have entered into new agreements outlining terms for potential termination scenarios and change-in-control events, ensuring clarity and continuity.
IDEXX LABORATORIES INC /DE 8-K Report, Material Agreement (Nov 13, 2025)
IDEXX LABORATORIES INC /DE (IDXX) filed an 8-K on November 12, 2025, detailing an amendment to its credit agreement. This amendment, specifically Amendment No. 2 to the Fourth Amended and Restated Credit Agreement, primarily extends the maturity dates for its revolving credit facility and introduces a new term loan facility. The revolving credit facility will now mature five years from the amendment's closing date, while the new term loan facility will mature three years from closing. This strategic move enhances the company's financial flexibility and extends its debt maturity profile. The total credit facility remains at $1.0 billion for the revolving line, with an additional $250 million for the term loan, and includes the option to incur up to an additional $250 million in incremental commitments. Borrowings can be used for general corporate purposes, providing management with resources for ongoing operations and potential strategic initiatives.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Nov 3, 2025)
IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K report on November 3, 2025, to announce its financial results for the third quarter ended September 30, 2025. The report primarily serves to furnish a press release detailing these results, which is attached as Exhibit 99.1. This filing does not contain extensive new operational details but rather directs investors to the accompanying press release for a comprehensive overview of the company's performance during the quarter. Investors should refer to the press release (Exhibit 99.1) for specific financial metrics, including revenue, earnings per share, and any forward-looking guidance or commentary provided by management. While the 8-K itself is a procedural filing, the furnished press release is the key document for understanding IDEXX's recent financial health and future outlook.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Oct 7, 2025)
IDEXX Laboratories, Inc. (IDXX) has announced a change to its Board of Directors through an 8-K filing dated October 7, 2025. Effective October 6, 2025, Karen Peacock was elected as an independent Class I Director. This appointment increases the total number of directors from ten to eleven and strengthens the board's expertise by adding Ms. Peacock to both the Compensation and Talent Committee and the Finance Committee. Ms. Peacock's election is a strategic move to enhance board oversight and expertise in key areas relevant to the company's ongoing operations and strategic initiatives.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Aug 4, 2025)
IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K to announce its financial results for the second quarter ended June 30, 2025. The report primarily furnishes a press release detailing these results, which investors should review for comprehensive financial performance insights. This filing does not contain new audited financial statements but serves as the official channel for disseminating the company's quarterly earnings information as of August 4, 2025.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Jul 10, 2025)
IDEXX Laboratories, Inc. (IDXX) announced a significant change to its Board of Directors with the election of Joseph L. (Jay) Hooley as an independent Class III Director, effective July 10, 2025. This appointment also includes his membership on the Audit Committee and Governance and Corporate Responsibility Committee. To accommodate Mr. Hooley's addition, the Board's size has been expanded from nine to ten directors, with an increase in Class III Directors from three to four. Mr. Hooley, an independent director, has no reported related party transactions with the Company. His compensation will align with that of other non-employee Directors, with prorated cash fees for the current quarter and prorated equity grants (deferred stock units or restricted stock units and stock options) to be issued on September 1, 2025. He will also be eligible to participate in the Company's Director Deferred Compensation Plan. The company issued a press release on July 10, 2025, detailing this appointment, which is furnished as an exhibit to this filing.
IDEXX LABORATORIES INC /DE 8-K Report, Bylaw Amendment (May 9, 2025)
IDEXX LABORATORIES INC /DE (IDXX) has filed an 8-K report detailing significant amendments to its corporate governance documents, effective May 7, 2025. The company has eliminated its Series A Junior Participating Preferred Stock, returning these shares to undesignated preferred stock status. More critically for investors, the company's Certificate of Incorporation and By-Laws have been amended to remove supermajority voting requirements and to allow for officer exculpation, aligning with recent Delaware law changes. These changes were approved by the Board of Directors and subsequently ratified by stockholders at the Annual Meeting held on May 7, 2025.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (May 1, 2025)
IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K on May 1, 2025, to report its financial results for the first quarter ended March 31, 2025. The filing primarily consists of a press release announcing these results, which is furnished as an exhibit. Investors should note that while this report provides key financial performance indicators, the information is furnished and not deemed "filed" for regulatory purposes, meaning it doesn't carry the same legal implications as a fully filed document under Section 18 of the Exchange Act. This announcement is critical for stakeholders seeking to understand the company's recent performance and its trajectory for the remainder of the fiscal year. While the specific financial figures and operational details are contained within the attached press release (Exhibit 99.1), this 8-K filing serves as the official notification of their availability. Investors are encouraged to review the press release for a comprehensive understanding of the quarter's results, including revenue, earnings, and any forward-looking guidance provided by the company.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Feb 14, 2025)
IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K reporting the immediate resignation of Dr. Asha Collins from its Board of Directors, effective February 13, 2025. The company explicitly states that Dr. Collins' departure was not due to any disagreements regarding the company's operations, policies, or practices. This event has resulted in a reduction of the Board's size from ten to nine directors. The company expressed gratitude for Dr. Collins' contributions during her time on the Board. While this filing does not contain financial results or strategic updates, the departure of a director, even under amicable circumstances, is a noteworthy event for investors. It may prompt questions about board composition, governance, and any potential implications for future decision-making. Investors should monitor future filings for any information regarding the replacement of Dr. Collins or changes in board committee memberships.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Feb 3, 2025)
IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report on February 3, 2025, to announce its financial results for the fourth quarter and full year ended December 31, 2024. The report itself primarily serves to furnish the press release containing these results, which is attached as Exhibit 99.1. Investors should refer to the press release for detailed financial performance, operational achievements, and forward-looking statements. This filing indicates that the company has met its reporting obligations by disclosing its latest financial outcomes. While the 8-K itself is a procedural filing, the accompanying press release is expected to provide critical insights into IDEXX's revenue growth, profitability, segment performance (such as diagnostics and software), and any strategic updates or outlook for the upcoming fiscal year. Investors will be keen to understand how the company performed against expectations and its long-term growth trajectory.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Dec 12, 2024)
IDEXX LABORATORIES INC /DE (IDXX) announced on December 11, 2024, the adoption of a new Nonqualified Deferred Compensation Plan, effective December 6, 2024. This plan allows a select group of management and highly compensated employees to voluntarily defer a portion of their base salary, annual bonus, and Stock Units. The primary purpose of this plan is to provide tax-advantaged savings opportunities for key personnel, aligning with Section 409A of the Internal Revenue Code. While the company has no current intention to make discretionary contributions, the plan allows for such contributions in the future, with specific vesting conditions. Distributions can occur upon separation from service, specified dates, death, or unforeseen emergencies, with settlement typically in cash, except for Stock Unit deferrals which will be settled in company common stock. This initiative aims to enhance executive compensation and retention strategies by offering a flexible and tax-efficient way for participants to save for the future.
IDEXX LABORATORIES INC /DE 8-K Report, Corporate Update (Dec 9, 2024)
IDEXX Laboratories, Inc. (IDXX) announced on December 9, 2024, a significant expansion of its share repurchase program. The Finance Committee of the Board of Directors authorized the repurchase of up to five million additional shares of common stock. This move indicates management's confidence in the company's financial health and its commitment to returning value to shareholders. The new authorization is in addition to the 1.3 million shares remaining under the existing program, substantially increasing the capital available for buybacks. These repurchases can be executed through various methods, including open market transactions and Rule 10b5-1 plans, providing flexibility for management. The program has no expiration date and can be adjusted as needed, signaling a potentially ongoing effort to manage its share count. Investors should view this as a positive signal of capital discipline and shareholder return strategy, potentially supporting the stock price.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Nov 21, 2024)
IDEXX Laboratories, Inc. (IDXX) announced a significant leadership transition for its Chief Financial Officer role. Brian P. McKeon, who has served as Executive Vice President, Chief Financial Officer, and Treasurer since 2014, will retire effective June 1, 2025. Mr. McKeon will transition from his CFO duties on March 1, 2025, to serve as a Special Advisor to ensure a smooth handover. The company has appointed Andrew Emerson, currently Senior Vice President of Finance for the Companion Animal Group (CAG) and Corporate Finance, to succeed Mr. McKeon as Executive Vice President, Chief Financial Officer, and Treasurer, effective March 1, 2025. Mr. Emerson brings extensive finance experience within IDEXX and prior to that at Medtronic. This transition is a key event for investors to note, as financial leadership continuity and compensation packages are crucial for evaluating company strategy and performance.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Nov 12, 2024)
IDEXX LABORATORIES INC /DE (IDXX) filed an 8-K on November 11, 2024, reporting a significant change in its Board of Directors. Jonathan W. Ayers, a long-serving former executive and director, resigned from the Board and its finance committee effective November 8, 2024. The company stated that Mr. Ayers's departure was not due to any disagreements regarding company operations, policies, or practices. Mr. Ayers had a substantial tenure with IDXX, having served as Chairman, President, and CEO from 2002 to 2019, and as a non-employee director until his recent resignation. The Board expressed gratitude for his over two decades of service and contributions. Following his resignation, the size of the Board has been reduced from eleven to ten directors. The filing also includes his resignation letter as an exhibit.
IDEXX LABORATORIES INC /DE 8-K Report, Material Agreement (Nov 6, 2024)
IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report to disclose amendments to its material definitive agreements concerning the supply of dry slides for its veterinary chemistry analyzers. These amendments, effective October 31, 2024, extend the supply agreements with Ortho-Clinical Diagnostics, Inc. through the end of 2044 for both U.S. and European operations. The key changes involve a significant extension of the contract expiration dates and modifications to the pricing structures, including adjustments to volume tiers and associated pricing over the extended contract terms. These amendments are crucial for ensuring the continued supply of a critical component for IDEXX's diagnostic instruments, providing long-term operational stability and predictability.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Oct 31, 2024)
IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report on October 31, 2024, to announce its financial results for the third quarter ended September 30, 2024. The report primarily serves to furnish the company's earnings press release, which contains the detailed financial performance and operational updates for the period. Investors should refer to Exhibit 99.1 for the complete earnings announcement. This filing does not contain new financial statements or significant operational changes beyond what is disclosed in the accompanying press release. The information furnished is for informational purposes and is not deemed "filed" for purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference into other filings. The Chief Financial Officer, Brian P. McKeon, signed the report.
IDEXX LABORATORIES INC /DE 8-K/A Report, Financial Results (Oct 31, 2024)
IDEXX Laboratories, Inc. (IDXX) has filed an amendment to its prior 8-K filing, specifically to correct an error in its previously issued earnings release from October 31, 2024. The amendment pertains to the company's financial outlook for the full year 2024. Investors should note that the projected range for comparable operating profit margin expansion has been revised downwards. The original earnings release projected a 70 to 100 basis point expansion, but this amendment clarifies that the actual expected range is now 30 to 60 basis points. All other financial results and forward-looking statements from the original release remain unchanged. This revision suggests a recalibration of the company's internal profit margin targets for the remainder of the fiscal year.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Aug 6, 2024)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on August 6, 2024, to report its financial results for the second quarter ended June 30, 2024. The core of this filing is the press release (Exhibit 99.1) containing the detailed financial performance for the period. Investors should refer to this press release for specific figures related to revenue, profitability, and any forward-looking statements or guidance provided by the company. This filing serves as the official channel for disseminating these results, making the press release a crucial document for understanding IDXX's recent operational and financial standing. While the 8-K itself is procedural, the furnished press release contains the substance of the company's performance updates, which are essential for investment analysis and decision-making. Investors are encouraged to review Exhibit 99.1 for a comprehensive understanding of IDXX's Q2 2024 performance.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (May 10, 2024)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 9, 2024, detailing two primary events: a consulting agreement with a former executive and the results of its 2024 annual shareholder meeting. Effective May 7, 2024, James F. Polewaczyk, formerly an Executive Vice President who retired on April 1, 2024, entered into a one-year consulting agreement. Under this agreement, Mr. Polewaczyk will provide coaching and professional development support to select employees for a fee of $25,000 per month. The annual meeting, held on May 6, 2024, saw shareholders approve all presented proposals. Key outcomes include the election of four Class I directors, the ratification of PricewaterhouseCoopers LLP as the independent registered accounting firm, and an advisory vote to approve executive compensation. Additionally, a shareholder proposal regarding simple majority vote was put to a vote and was approved by a majority of shareholders.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (May 1, 2024)
IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K on May 1, 2024, to announce its financial results for the quarter ended March 31, 2024. The report primarily furnishes a press release detailing these results, which is attached as Exhibit 99.1. Investors should note that this information, while crucial for understanding the company's performance, is being furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal implications of filed documents unless specifically incorporated by reference into other filings. The core of this filing is the attached press release, which provides the company's operational and financial outcomes for the first quarter of 2024. While the 8-K itself is a procedural document, investors are advised to refer to the furnished press release (Exhibit 99.1) for the specific financial metrics, performance trends, and any forward-looking statements or management commentary related to the quarter's results. The filing also lists the Chief Financial Officer and Treasurer as signing for the company, indicating the official release of this information.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Feb 5, 2024)
IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K on February 5, 2024, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2023. The report itself is brief, acting as a cover for the more detailed press release furnished as Exhibit 99.1. Investors should refer to this press release for comprehensive details on the company's performance, including key financial metrics, operational achievements, and any forward-looking statements or guidance.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Dec 7, 2023)
IDEXX Laboratories, Inc. (IDXX) announced on December 5, 2023, that its Executive Vice President and Chief Commercial Officer, James F. Polewaczyk, will retire effective April 1, 2024. Mr. Polewaczyk has served the company in leadership capacities for over 17 years, contributing significantly to its commercial operations and growth. This departure marks the end of a long tenure for a key executive. Investors will likely want to understand the succession plan for this critical role and how Mr. Polewaczyk's departure might impact the company's commercial strategy and execution moving forward. While the filing does not provide details on a successor, it indicates a planned transition, allowing time for leadership to address this change.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Nov 1, 2023)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on November 1, 2023, to report its financial results for the third quarter ended September 30, 2023. The report primarily serves to furnish the press release detailing these results, which provides investors with the company's latest performance metrics. Specific financial figures and operational highlights are contained within the furnished press release (Exhibit 99.1), which is the key document for investors to review for detailed insights into the company's performance during the quarter. While the 8-K itself does not contain the detailed financial data, it officially announces the availability of IDEXX's third-quarter results. Investors seeking to understand the company's revenue, profitability, segment performance, and any forward-looking statements or guidance should refer to the press release attached as Exhibit 99.1. This filing signifies the company's adherence to timely disclosure requirements regarding its financial condition and operational outcomes.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Aug 1, 2023)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on August 1, 2023, primarily to announce its financial results for the second quarter ended June 30, 2023. While the filing itself is brief, it directs investors to a furnished press release (Exhibit 99.1) for the detailed financial performance and operational updates. This is a standard disclosure for earnings announcements, indicating that the company's performance metrics are available for investor review through the accompanying press release.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Jul 12, 2023)
IDEXX Laboratories, Inc. (IDXX) announced a change in its Board of Directors through an 8-K filing on July 12, 2023. The company elected Irene Chang Britt as an independent Class I Director, effective July 11, 2023. This appointment also includes her joining the Audit Committee and the Compensation and Talent Committee. To accommodate this addition, the size of the Board has been expanded from ten to eleven directors, with the number of Class I Directors increasing from three to four. Ms. Chang Britt's appointment is notable as she has no disclosed related-party transactions. Her compensation will align with that of other non-employee directors, with adjustments reflecting recent increases in annual retainers and equity awards approved in May 2023. Specifically, her annual cash retainer will be $90,000, and her annual equity compensation will be valued at $250,000, split evenly between full-value awards and stock options. These will be prorated to reflect her service period from July 11, 2023, to the 2024 annual meeting. The company also issued a press release on July 12, 2023, to announce this board change.
IDEXX LABORATORIES INC /DE 8-K Report, Shareholder Vote Results (May 19, 2023)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K report detailing the results of its 2023 Annual Meeting of Shareholders, held on May 17, 2023. The primary purpose of this filing was to report the voting outcomes on several key proposals. Investors should note that all proposed items, including the election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and advisory votes on executive compensation and its frequency, received majority shareholder approval. The election of directors Daniel M. Junius, Lawrence D. Kingsley, and Sophie V. Vandebroek was successful, with significant "For" votes compared to "Against" and "Abstain" votes, ensuring continued board leadership. Shareholders also overwhelmingly ratified the appointment of PricewaterhouseCoopers LLP, indicating confidence in their financial oversight. Furthermore, the advisory vote to approve executive compensation passed, and the company will hold an advisory vote on executive compensation annually, as decided by the shareholders.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (May 2, 2023)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 2, 2023, to report its financial results for the first quarter ended March 31, 2023. While the 8-K itself is a brief filing, it serves as a notification that the company has released its detailed financial performance in an accompanying press release, furnished as Exhibit 99.1. Investors should refer to the press release for comprehensive details on revenue, earnings, and any forward-looking guidance. This 8-K filing primarily signals the availability of these crucial Q1 2023 financial updates and does not contain new substantive operational or financial data within the 8-K document itself.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Feb 6, 2023)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on February 6, 2023, to announce its financial results for the fourth quarter and full year ended December 31, 2022. The report primarily furnishes the press release detailing these results, which should be reviewed for comprehensive financial and operational information. Investors should note that this information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act, meaning it does not carry the same liability implications, nor is it automatically incorporated into other filings unless specifically referenced. The core of this filing is the attached press release (Exhibit 99.1), which provides the quantitative and qualitative details of IDEXX's performance. While the 8-K itself does not contain the detailed financial statements or operational analysis, it serves as the official notification mechanism for the market to access this crucial information directly from the company. Investors seeking to understand IDEXX's recent financial health and operational standing are directed to review the furnished press release.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Nov 1, 2022)
IDEXX Laboratories, Inc. (IDXX) filed a Form 8-K on November 1, 2022, to report its financial results for the third quarter ended September 30, 2022. The filing primarily serves as a notification of the earnings release, which is furnished as an exhibit. Investors should refer to the press release (Exhibit 99.1) for detailed financial performance and operational updates for the quarter. This report itself does not contain the specific financial figures but points investors to the official announcement for that information.
IDEXX LABORATORIES INC /DE 8-K Report, Material Agreement (Oct 21, 2022)
IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report detailing an amendment to its existing $1.0 billion unsecured revolving credit facility. This amendment, effective October 20, 2022, introduces significant changes, including the immediate borrowing of $250 million in incremental term loans. Furthermore, the company has transitioned its existing LIBOR-based borrowings to SOFR-based interest rates, aligning with industry-wide shifts away from LIBOR. The amendment also provides IDEXX with the flexibility to potentially increase its total credit facility to up to $1.5 billion, subject to securing additional commitments from lenders. This strategic move enhances the company's financial flexibility and provides resources for general corporate purposes. The amendment outlines updated interest rate structures for various currencies, primarily referencing SOFR for USD borrowings, and includes customary covenants and events of default.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Aug 2, 2022)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on August 2, 2022, to announce its financial results for the second quarter ended June 30, 2022. The company's press release, furnished as an exhibit, details the performance for the period. This filing provides investors with the latest official financial data, including revenue, earnings, and potentially other key operational metrics, allowing for an assessment of the company's recent performance and its trajectory. While the filing itself is a procedural notification of the earnings release, the underlying press release (Exhibit 99.1) is the primary source of financial and operational insights for investors. Investors should refer to this press release for details on revenue generation, profitability, any updated financial guidance, and management's commentary on business drivers and market conditions. The information furnished under Item 2.02 is crucial for understanding IDEXX's performance against expectations and its strategic positioning in the animal health diagnostics market.
IDEXX LABORATORIES INC /DE 8-K Report, Bylaw Amendment (Jul 15, 2022)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on July 14, 2022, to report amendments to its bylaws, effective July 13, 2022. The primary change relates to director nominations, specifically aligning stockholder notice requirements with the SEC's newly adopted Rule 14a-19 (b)(iii). This amendment modifies the information a stockholder must provide when nominating a director candidate, particularly regarding their intent to deliver a proxy statement and/or form of proxy to a significant portion of the voting power of the company's capital stock. The key adjustment requires stockholders to represent whether they intend to deliver proxy materials to holders representing at least 67% of the voting power for director elections, a change from the previous standard of a percentage reasonably believed sufficient to elect a nominee. While this is a technical update to comply with new SEC regulations, it primarily impacts the procedural requirements for shareholder nominations rather than altering fundamental corporate governance or financial performance metrics. The filing also notes other minor, non-substantive changes within the Amended Bylaws.
IDEXX LABORATORIES INC /DE 8-K Report, Regulation FD Disclosure (Jun 14, 2022)
IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report to disclose its decision to wind down and liquidate its sole Russian subsidiary and direct operations in Russia. This decision follows a significant scaling back of its Russian activities since March 2022, which included suspending sales of veterinary diagnostic equipment, promotional activities, and new business development. The company emphasized that its Russian operations represented less than 1% of its 2021 consolidated revenue, and it has no manufacturing or significant supply arrangements within Russia. While the company is focused on providing transition support to its impacted Russian employees, it anticipates that a limited number of its essential human or animal healthcare products may continue to be sold in Russia through existing third-party distribution agreements after the wind-down is complete. This move aims to formally exit the Russian market while minimizing disruption to essential healthcare supplies and addressing its responsibilities to its employees.
IDEXX LABORATORIES INC /DE 8-K Report, Shareholder Vote Results (May 13, 2022)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 13, 2022, to report the results of its 2022 annual meeting of shareholders held on May 11, 2022. The primary focus of the filing is the voting outcomes on key corporate matters, including the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation. Shareholders overwhelmingly approved all proposals presented. The election of four Class III directors, Jonathan W. Ayers, Stuart Essig, PhD, Jonathan J. Mazelsky, and M. Anne Szostak, for terms expiring in 2025, received substantial support. Similarly, the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year was ratified with strong approval. The advisory vote to approve executive compensation also passed with a significant majority, indicating shareholder confidence in the company's leadership and governance.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (May 4, 2022)
IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K on May 4, 2022, to announce its financial results for the first quarter ended March 31, 2022. The company is furnishing the press release detailing these results as an exhibit to this filing. Investors should note that the information provided is furnished under Item 2.02 and is not considered "filed" under the Securities Exchange Act of 1934, meaning it doesn't carry the same legal liabilities or automatic incorporation by reference into other SEC filings, unless explicitly stated. While the specific financial details are within the furnished press release (Exhibit 99.1), this 8-K serves as the official notification of the results' release. Investors seeking to understand IDEXX's performance for the first quarter of 2022, including revenue, profitability, and any forward-looking guidance or commentary provided by management, will need to refer to the accompanying press release.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Feb 2, 2022)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on February 2, 2022, to announce its financial results for the fourth quarter and full year ended December 31, 2021. The report primarily furnishes the press release detailing these results, which is available as Exhibit 99.1. Investors should note that this information is furnished, not filed, and therefore does not carry the same liabilities under Section 18 of the Exchange Act. However, the press release itself contains the critical financial performance data for the period. The furnished press release provides the company's operational and financial condition updates. While the 8-K filing itself does not contain the detailed financial figures, it directs investors to the press release for comprehensive information regarding revenue, profitability, and other key financial metrics for both the quarter and the full year. Investors looking for specific performance indicators will need to refer to Exhibit 99.1.
IDEXX LABORATORIES INC /DE 8-K Report, Material Agreement (Dec 9, 2021)
IDEXX LABORATORIES INC /DE (IDXX) filed an 8-K on December 9, 2021, to disclose the execution of a Fourth Amended and Restated Credit Agreement. This agreement primarily concerns a $1 billion, five-year unsecured revolving credit facility maturing on December 9, 2026. The key update involves extending the maturity date from the previous agreement and retaining the $1 billion principal amount, with an option to increase it by an additional $250 million, subject to lender commitments and other conditions. The agreement also incorporates new borrowers (IDEXX Laboratories B.V. and IDEXX Laboratories GmbH) and updates interest rate benchmark mechanics to accommodate alternatives to LIBOR. From an investor's perspective, the extension of the credit facility provides continued financial flexibility and operational runway for the company. The ability to potentially increase the credit line offers headroom for future growth or strategic initiatives. Furthermore, the reduction in applicable interest rate margins suggests a potentially improved cost of borrowing and reflects a strong credit profile for IDEXX. The inclusion of new European subsidiaries as borrowers indicates the company's ongoing international expansion and operational integration.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Nov 2, 2021)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on November 2, 2021, to announce its financial results for the third quarter ended September 30, 2021. The key information provided in this filing is a press release detailing the company's performance during the quarter. This report serves as a notification of the results, and the details are within the furnished press release (Exhibit 99.1), which is not deemed 'filed' under Section 18 of the Exchange Act but is furnished for informational purposes. Investors should refer to the press release issued on November 2, 2021, for specific financial metrics, including revenue, earnings per share, and any forward-looking guidance. This 8-K filing itself primarily confirms the release of this information and its availability to the public.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Jul 30, 2021)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on July 30, 2021, to announce its financial results for the second quarter ended June 30, 2021. The filing primarily includes a press release furnishing these results, which is treated as furnished information under Item 2.02 and not formally 'filed' for certain regulatory purposes. Investors should refer to the press release (Exhibit 99.1) for the detailed financial performance and operational updates for the quarter. The 8-K itself serves as a notification vehicle for this information release.
IDEXX LABORATORIES INC /DE 8-K Report, Shareholder Vote Results (May 18, 2021)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 17, 2021, detailing the outcomes of its 2021 Annual Meeting of Shareholders held on May 12, 2021. The primary focus of this filing is the voting results on several key proposals, including the election of directors, the ratification of PricewaterhouseCoopers LLP as the independent registered accounting firm, and an advisory vote on executive compensation. Investors can find assurance in the overwhelming support for each of these proposals, indicating strong shareholder confidence in the company's leadership and financial oversight. The election of four directors, Bruce L. Claflin, Asha S. Collins, PhD, Daniel M. Junius, and Sam Samad, received significant approval. The ratification of PricewaterhouseCoopers LLP as the auditor was also strongly supported, reinforcing the integrity of the company's financial reporting processes. Furthermore, the advisory vote to approve executive compensation passed with a substantial majority, suggesting that shareholders are aligned with the company's compensation strategies for its named executive officers.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (May 4, 2021)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 4, 2021, to report its financial results for the first quarter ended March 31, 2021. The filing includes a press release that details the company's performance during the period. Investors should refer to the furnished press release (Exhibit 99.1) for specific financial figures and operational updates. This report serves as a notification of the released earnings and does not constitute a change in previously disclosed financial information. The information provided is furnished and not considered "filed" for regulatory purposes, meaning it does not carry the same liability under Section 18 of the Securities Exchange Act of 1934. Investors seeking detailed financial performance metrics, revenue breakdowns, and forward-looking guidance should consult the referenced press release.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Feb 10, 2021)
IDEXX LABORATORIES INC /DE (IDXX) has filed an 8-K report on February 9, 2021, to announce the upcoming retirement of Dr. Rebecca M. Henderson from its Board of Directors. Her retirement is effective immediately following the Company's 2021 Annual Meeting of Stockholders scheduled for May 12, 2021. This departure is not attributed to any disagreements regarding the company's operations, policies, or practices, which suggests a smooth transition and continued alignment within the board. Investors should note that while the departure of a board member can sometimes signal shifts, the company explicitly states Dr. Henderson's decision is based on her intention to retire. The company has expressed gratitude for her significant contributions during her tenure. This event, while notable, appears to be a planned succession rather than a reaction to internal conflict, and investors can anticipate further updates regarding board composition post-annual meeting.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Feb 2, 2021)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on February 2, 2021, to report its financial results for the fourth quarter and full year ended December 31, 2020. The filing primarily consists of a press release announcing these results, which is furnished as Exhibit 99.1. While the 8-K itself does not contain detailed financial tables, it directs investors to the press release for comprehensive information regarding the company's performance during the specified periods. Investors should review the furnished press release for key financial metrics, including revenue, earnings per share, and any forward-looking guidance provided by IDEXX. This report marks the official communication of the company's year-end and fourth-quarter financial standing, offering insights into its operational and financial condition. The information provided is furnished and not deemed 'filed' under the Securities Exchange Act of 1934.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Nov 12, 2020)
IDEXX Laboratories, Inc. (IDXX) announced the election of Dr. Asha S. Collins as an independent Class I Director to its Board of Directors, effective November 11, 2020. This appointment increases the Board size from ten to eleven directors and adds Dr. Collins to the Nominating and Governance Committee. This move signals a commitment to strengthening board oversight and governance with diverse expertise. Investors should note that Dr. Collins has no related party transactions and will receive standard compensation for non-employee directors, prorated for her partial year service. The company also furnished a press release detailing this appointment, which is attached as an exhibit. This proactive board expansion is a positive development, indicating the company's focus on strategic growth and robust corporate governance. Investors can look forward to Dr. Collins's contributions, particularly in the areas of nominations and governance, as she is expected to stand for election by stockholders at the 2021 annual meeting.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Oct 29, 2020)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on October 29, 2020, to report its financial results for the third quarter ended September 30, 2020. The key information for investors is contained within the press release furnished as Exhibit 99.1, which details the company's performance during the period. While the 8-K itself is a procedural filing to announce these results, the underlying press release would provide specific metrics such as revenue, earnings per share, and segment performance within the veterinary diagnostics and software markets.